Skip to main content
. Author manuscript; available in PMC: 2018 May 31.
Published in final edited form as: Curr Alzheimer Res. 2016;13(6):610–614. doi: 10.2174/1567205013666151221145445

Fig. 2. Hsp60 levels are up-regulated in AD.

Fig. 2

(A) Representative western blot (lower panel) shows a relative increase in Hsp60-immunoreactive signals in sporadic AD (sAD) and familial (fAD) cases compared to controls (CTL). The blot was stripped and re-probed for mtHsp70 as a loading control (see Materials and Methods). Note that mtHsp70 signals on the same blot (upper panel) remain constant across the cases. (B) Quantitative analysis of Hsp60-immunoreactive signals normalized to mtHsp70 reveals a step-wise increase in Hsp60 protein levels in sAD and fAD, respectively, compared to CTL. Hsp60 levels in fAD were significantly higher compared to sAD. *p < 0.05 vs. CTL; ** p < 0.01 vs. CTL; # p < 0.05 vs. sAD.